Correction to: Nature Reviews Clinical Oncology https://doi.org/10.1038/s41571-020-00447-z, published online 8 December 2020.
In the original version of this Evidence-Based Guidelines, Fig. 3 contained errors regarding unfavourable factors for IDH-wild-type glioblastomas, WHO grade 4. The box label originally mentioning “KPS <70 years” has been corrected to “age <70 years; KPS <70 years”. In addition, greater clarity has been provided by changing “age >70 years” in other boxes to “age ≥70 years”. Fig. 3 has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Weller, M., van den Bent, M., Preusser, M. et al. Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 19, 357–358 (2022). https://doi.org/10.1038/s41571-022-00623-3
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41571-022-00623-3
This article is cited by
-
Cerebrospinal fluid cfDNA-based molecular assessment of resection extent and prognosis in glioma
Communications Medicine (2026)
-
Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models
Cell Death Discovery (2025)
